[A multicenter clinical trial of SMS 201-995 (octreotide acetate) in acromegaly and gigantism].

Abstract

Sixty-four patients with active acromegaly and three patients with gigantism were treated with the long acting somatostatin analog SMS 201-995 (50-500 micrograms, sc, every 6-12 h or 150-880 micrograms daily by intermittent sc infusion, for up to 114 weeks). The fasting plasma GH levels were significantly suppressed (less than 50% of the values before treatment) in 49 patients and became normal in 18 patients. Suppression of GH secretion was associated with normalization of plasma somatomedin-C levels (14 out of 30 cases) and significant clinical improvement such as disappearance of headache and decrease of excessive sweating. Shrinkage of pituitary tumors as determined by computed tomography and/or magnetic resonance imaging studies occurred in 11 out of 40 cases. Side effects were minimal and tolerable. SMS 201-995 appears to be an effective agent for the treatment of acromegaly and gigantism.

• Authors: A Shimatsu, H Imura, M Irie, S Nakagawa, Y Goto, N Shimizu, R Takeda, Y Kato, S Saito, H Ibayashi
• Journal: Nihon Naibunpi Gakkai zasshi (Nihon Naibunpi Gakkai Zasshi) Vol. 65 Issue 7 Pg. 640-52 (Jul 20 1989) ISSN: 0029-0661 [Print] Japan
• PMID: 2684694 (Publication Type: Clinical Trial, English Abstract, Journal Article, Multicenter Study)

Chemical References

• Insulin-Like Growth Factor I
• Growth Hormone
• Octreotide

Topics

• Acromegaly (blood, drug therapy)
• Adolescent
• Adult
• Aged
• Clinical Trials as Topic
• Female
• Gigantism (blood, drug therapy)
• Growth Hormone (blood)
• Humans
• Insulin-Like Growth Factor I (metabolism)
• Japan
• Male
• Middle Aged
• Multicenter Studies as Topic
• Octreotide (pharmacokinetics, therapeutic use)